Dr Reddy's survives equity turmoil

The company has become the first Asian pharmaceutical company to list on the New York Stock Exchange.
April 12, 2001
In the face of exceptionally trying equity markets, India's third largest pharmaceuticals company has fulfilled its ambitions and in doing so, managed to achieve parity pricing for its debut ADR.

With Merrill Lynch as lead manager, an 11.5 million unit issue was priced yesterday (Wednesday) at $10.04 per unit. Each unit equals two shares, with the overall offering comprising about 18% of the company's share capital. ABN AMRO and CLSA are co-managers.

Sign in to read on!

Registered users get 2 free articles in 30 days.

Subscribers have full unlimited access to FinanceAsia.

Not signed up? New users get 2 free articles per month, plus a 7-day unlimited free trial.

Questions?
See here for more information on licences and prices, or contact [email protected].

Share our publication on social media
Share our publication on social media